Evidence map›Paper›PMID 12756418›Full record

ReviewGene therapy2003

Immune response following intraocular delivery of recombinant viral vectors.

J Bennett

Abstract readReview
PubMed Publisher
In one paragraph

Review in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. CRISPR/Cas systems: Delivery and application in gene therapy.Frontiers in bioengineering and biotechnology · 2022
    Review
  14. Review
  15. Review
  16. Cav1.4 dysfunction and congenital stationary night blindness type 2.Pflugers Archiv : European journal of physiology · 2021
    Review
  17. Safety of Same-Eye Subretinal Sequential Readministration ofMolecular therapy. Methods & clinical development · 2019
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

J BennettFM Kirby Center for Molecular Ophthalmology, Scheie Eye Institute, University of Pennsylvania, Philadelphia, PA 19104-6069, USA.

Funding

GENETIC THERAPY OF A HEREDITARY RETINAL DEGENERATIONR01EY010820 · NEI · UNIVERSITY OF PENNSYLVANIA · PI BENNETT, JEAN · 1995 to 2007
$3.5M
ANIMAL MODELS FOR A HEREDITARY MACULAR DEGENERATONR01EY012156 · NEI · UNIVERSITY OF PENNSYLVANIA · PI BENNETT, JEAN · 1998 to 2004
$1.8M
NEI NIH HHS EY12156NEI NIH HHS R01EY10820PHS HHS U10 013729
6 · The paper itself

Abstract

There has been significant progress in the last few years in demonstrating the utility of recombinant viral vectors in treating a variety of ocular diseases. The field has moved beyond 'proof-of-principle' and, in fact, has entered the phase where some of these vectors/paradigms are being or soon will be evaluated in human clinical trials. For this reason and also, to increase the understanding of immunological effects of transgenes/viral vectors on the eye, it is important to summarize what is known about these effects. Here, the biology of and immune responses to intraocular injection of three different recombinant viral vectors - adenovirus, adeno-associated virus (AAV), and lentivirus - are summarized. Perhaps, in part because of the unique immunological environment of the eye, the immunological effects of these viruses appear to be fairly benign. Nevertheless, a significant cell-mediated immune response can develop after intraocular administration of adenovirus. The magnitude of this response is affected by the nature of the intraocular compartment to which this virus is administered. Neither AAV nor lentivirus, however, elicit a cell-mediated response and are thus promising vectors for treatment of chronic ocular (retinal) diseases.

Indexed as

AdenoviridaeAnimalsAntibodies, ViralAntigen-Presenting CellsDependovirusEyeEye DiseasesGenetic TherapyGenetic VectorsHumansInjectionsLentivirusRecombinant ProteinsTransduction, GeneticAntibodies, ViralRecombinant Proteins

Identifiers

PMID12756418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.